Safety of the use of anti-IL17A treatment in a patient with certolizumab-induced sarcoidosis

1, 2, 3

  1. INSERM CIC-1431, Clinical Investigation Center in Biotherapy; Fédération Hospital-Universitaire INCREASE; Dept. of Rheumatology, University Hospital of Besançon; Univ. of Bourgogne Franche-Comté, Dept. of Therapeutics and EPILAB EA4266, Besançon, France.
  2. Department of Nephrology, Hôpital Nord Franche-Comté, Trevenans, France.
  3. Department of Rheumatology, Hôpital Nord Franche-Comté, Trevenans, France.

CER11613 Submission on line
2019 Vol.37, N°2 - PI 0344, PF 0345

Free to view (click on article PDF icon to read the article)

Rheumatology Article


PMID: 30873944 [PubMed]

Received: 12/08/2018 - Accepted : 09/10/2018 - In Press: 07/03/2019 - Published: 19/03/2019